{
    "body": "For which type of diabetes can empagliflozin be used?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23398530", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24943000", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26557225", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25692841", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23906374", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22268612", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24186878", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25598831", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24843716", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24746173", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25712444", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25644093", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24795251", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24991224", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25274537", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25941565", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24944269", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23940010", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25332189", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24964723", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25301180", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24948511", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24622369", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24007456", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24463454", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25775379"
    ], 
    "ideal_answer": [
        "The oral antidiabetes agent, empagliflozin, can be used as monotherapy or alongside other glucose-lowering treatments, including insulin, to treat T2DM."
    ], 
    "exact_answer": [
        "type 2 diabetes mellitus"
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003924", 
        "http://www.disease-ontology.org/api/metadata/DOID:9352"
    ], 
    "type": "factoid", 
    "id": "571e14fbbb137a4b0c000001", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 106, 
            "text": "Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: a review of the evidence.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25712444", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 11, 
            "offsetInEndSection": 257, 
            "text": "To review available studies of empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor approved in 2014 by the European Commission and the United States Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25712444", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1149, 
            "offsetInEndSection": 1422, 
            "text": "In Phase II trials in patients with type 2 diabetes, empagliflozin provided improvements in glycosylated hemoglobin (HbA1c) and other measures of glycemic control when given as monotherapy or add-on to metformin, as well as reductions in weight and systolic blood pressure.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24991224", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 77, 
            "text": "Empagliflozin: a review of its use in patients with type 2 diabetes mellitus.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25274537", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 1655, 
            "offsetInEndSection": 1774, 
            "text": "This article reviews the pharmacological properties and clinical use of empagliflozin in patients with type 2 diabetes.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25274537", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 108, 
            "text": "Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24991224", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 144, 
            "text": "To evaluate the pharmacodynamics, pharmacokinetics, safety and tolerability of empagliflozin in Japanese patients with type 2 diabetes mellitus.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24843716", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 120, 
            "text": "A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23398530", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 152, 
            "text": "Pharmacokinetics, pharmacodynamics, safety and tolerability of 4\u00a0weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24843716", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 364, 
            "offsetInEndSection": 481, 
            "text": "We assessed the efficacy and safety of empagliflozin as an add-on treatment in patients with type 2 diabetes and CKD.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24795251", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 306, 
            "offsetInEndSection": 499, 
            "text": "The SGLT-2 inhibitor empagliflozin improves glucose control, body weight and blood pressure when used as monotherapy or add-on to other antihyperglycemic agents in patients with type 2 diabetes", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24943000", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 253, 
            "text": "Data from five randomized, placebo-controlled, multiple oral dose studies of empagliflozin in patients with type 2 diabetes mellitus (T2DM; N\u2009=\u2009974; 1-100\u2009mg q.d.; \u226412 weeks) were used to develop a population pharmacokinetic (PK) model for empagliflozin", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23940010", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 214, 
            "text": "Empagliflozin, (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol was recently approved by the FDA for the treatment of chronic type 2 diabetes mellitus", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25332189", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 288, 
            "offsetInEndSection": 456, 
            "text": "The SGLT2 inhibitor empagliflozin has gained approval in the EU and in the USA for the treatment of adults with T2DM (there is no current indication in type 1 diabetes)", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25941565", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 156, 
            "text": "Pharmacokinetics, pharmacodynamics, safety and tolerability of 4\u00a0weeks&apos; treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24843716", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 318, 
            "offsetInEndSection": 513, 
            "text": "The SGLT-2 inhibitor empagliflozin improves glucose control, body weight and blood pressure when used as monotherapy or add-on to other antihyperglycemic agents in patients with type 2 diabetes. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24943000", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 157, 
            "text": "Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23906374", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 150, 
            "text": "The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24944269", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 243, 
            "text": "Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24007456", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 132, 
            "text": "Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24964723", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 118, 
            "text": "This article reviews the pharmacological properties and clinical use of empagliflozin in patients with type 2 diabetes.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25274537", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 240, 
            "text": "With its insulin-independent mechanism of action, empagliflozin monotherapy or combination therapy with other antidiabetic drugs, including insulin, provides a useful addition to the therapeutic options for the management of type 2 diabetes.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25274537", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 340, 
            "text": "In several phase III trials (104weeks' duration; typically 24weeks' duration) and extension studies (typically76weeks' treatment), empagliflozin monotherapy or add-on therapy to other antihyperglycaemics, including insulin, improved glycaemic control and reduced bodyweight and systolic blood pressure in adult patients with type 2 diabetes.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25274537", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 171, 
            "text": "Oral empagliflozin (Jardiance()), a sodium glucose cotransporter-2 (SGLT2) inhibitor, is a convenient once-daily treatment for adult patients with type 2 diabetes mellitus.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25274537", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 675, 
            "text": "Sodium glucose cotransporter 2 (SGLT2) inhibitors are a new class of treatment for T2DM that reduce hyperglycemia by reducing renal glucose reabsorption and thereby increasing urinary glucose excretion.This paper reviews the pharmacokinetic and pharmacodynamic properties of the SGLT2 inhibitor empagliflozin , the results of clinical trials investigating the efficacy of empagliflozin given as monotherapy or as add-on therapy on glycemic control, body weight, and blood pressure in patients with T2DM, and the safety and tolerability profile of empagliflozin.Empagliflozin offers good glycemic efficacy, weight loss, blood pressure reduction, and a low risk of hypoglycemia.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25301180", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 51, 
            "text": "Empagliflozin for the treatment of type 2 diabetes.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25301180", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 596, 
            "offsetInEndSection": 955, 
            "text": "This paper reviews the pharmacokinetic and pharmacodynamic properties of the SGLT2 inhibitor empagliflozin , the results of clinical trials investigating the efficacy of empagliflozin given as monotherapy or as add-on therapy on glycemic control, body weight, and blood pressure in patients with T2DM, and the safety and tolerability profile of empagliflozin.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25301180", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2286, 
            "offsetInEndSection": 2519, 
            "text": "In patients with type 2 diabetes and stage 2 or 3 CKD, empagliflozin reduced HbA1c and was well tolerated. However, our findings might not be applicable to the general population of patients with type 2 diabetes and renal impairment.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24795251", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1302, 
            "offsetInEndSection": 1663, 
            "text": "With its insulin-independent mechanism of action, empagliflozin monotherapy or combination therapy with other antidiabetic drugs, including insulin, provides a useful addition to the therapeutic options for the management of type 2 diabetes. This article reviews the pharmacological properties and clinical use of empagliflozin in patients with type 2 diabetes.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25274537", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1469, 
            "offsetInEndSection": 1715, 
            "text": "In patients with type 2 diabetes, empagliflozin resulted in dose-dependent, clinically meaningful reductions in HbA1c and FPG, and reductions in body weight compared with placebo. Empagliflozin was well-tolerated with a favourable safety profile.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23398530", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1405, 
            "offsetInEndSection": 1648, 
            "text": "No UTIs or genital infections led to premature discontinuation. In patients with type 2 diabetes, empagliflozin resulted in dose-dependent, clinically meaningful reductions in HbA1c and FPG, and reductions in body weight compared with placebo.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23398530", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1469, 
            "offsetInEndSection": 1648, 
            "text": "In patients with type 2 diabetes, empagliflozin resulted in dose-dependent, clinically meaningful reductions in HbA1c and FPG, and reductions in body weight compared with placebo.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23398530", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 882, 
            "offsetInEndSection": 1155, 
            "text": "In Phase II trials in patients with type 2 diabetes, empagliflozin provided improvements in glycosylated hemoglobin (HbA1c) and other measures of glycemic control when given as monotherapy or add-on to metformin, as well as reductions in weight and systolic blood pressure.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24991224", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1544, 
            "offsetInEndSection": 1663, 
            "text": "This article reviews the pharmacological properties and clinical use of empagliflozin in patients with type 2 diabetes.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25274537", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 121, 
            "text": "A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23398530", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 78, 
            "text": "Empagliflozin: a review of its use in patients with type 2 diabetes mellitus.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25274537", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 109, 
            "text": "Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24991224", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 1846, 
            "offsetInEndSection": 2116, 
            "text": "In patients with type 2 diabetes, empagliflozin-induced glycosuria improved \u03b2 cell function and insulin sensitivity, despite the fall in insulin secretion and tissue glucose disposal and the rise in EGP after one dose, thereby lowering fasting and postprandial glycemia.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24463454", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 94, 
            "text": "Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25775379", 
            "endSection": "title"
        }
    ]
}